Key Takeaways Segmental vitiligo (SV): early onset, unilateral/dermatomal distribution, rapid stabilization; best surgical candidate once stable. Nonsegmental vitiligo (NSV): bilateral/symmetric […]
Key Takeaways Face/neck respond fastest: perifollicular islands in 4–8 weeks, meaningful F-VASI drops by 8–12 weeks—best as nightly monotherapy or
Key Takeaways Backbone: NB-UVB 311 nm for generalized disease; excimer 308 nm for focal patches, rims, and acral borders. Face/folds: tacrolimus (±
Key Takeaways Indication: stable segmental or focal nonsegmental vitiligo that failed optimized medical/light therapy. Confirm stability: no new/enlarging lesions, quiet
Key Takeaways Why relapse? Persistent tissue-resident memory T cells (TRM) linger in previously affected skin and can reignite depigmentation after
Key Takeaways Face/neck first-line: topical calcineurin inhibitors (tacrolimus 0.03–0.1%) are preferred to avoid steroid atrophy. Generalized disease: NB-UVB 311 nm 2–3×/wk
Key Takeaways Segmental vitiligo (SV): early onset, unilateral/dermatomal streaks, rapid stabilization (months), poor response to light on acral—but excellent surgical
Key Takeaways Face/neck respond best to tacrolimus 0.1%, with earlier perifollicular islands and higher chances of achieving F-VASI50/75 when combined
Key Takeaways Backbone therapy for generalized/nonsegmental vitiligo; best responses on face/neck, slower on acral sites. Start low, escalate by 10–20%
